Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study.

ABSTRACT:

Background

Since giant cell tumors of bone (GCTB) and other giant cell rich tumors of bone (GCRTB) share the histological presence of osteoclastic giant cells and expression of RANK/RANKL, we hypothesized that GCRTB will respond similarly to denosumab as GCTB. The primary objective of this study was to determine the efficacy of denosumab in patients with GCRTB that have recurred or require morbid surgery.

Methods

In this open-label, multicenter, phase II trial, patients with GCRTB were included (June 2018-March 2020). Recruitment was stopped because of low accrual. Patients received denosumab (120 mg) subcutaneously (SC) on day 1 of every 4-week cycle with a loading dose of 120 mg SC on days 8 and 15.

Results

Three patients were enrolled. One withdrew consent before s

SUBMITTER: Lipplaa A 

PROVIDER: S-EPMC10628576 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature